SCHEMBL1024188

SCHEMBL1024188

Cc1ccc(Cc2nsc(NCCN)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
HTR6 P50406 1/20 0.36
LTA4H P09960 1/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
AR P10275 1/20 0.34
KMT2A Q03164 1/20 0.34
IKBKB O14920 2/20 0.33
CHUK O15111 2/20 0.33
MAPT P10636 2/20 0.33
ERN1 O75460 1/20 0.33
RPS6KA4 O75676 1/20 0.33
PRKD3 O94806 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020945 0.92 SYK (0.36) SMN1; SMN2NPC1RAB9ACYP1A2CYP2A6
SCHEMBL1021399 0.91 SYK (0.38) SMN1; SMN2NPC1RAB9ACYP1A2CYP2A6
SCHEMBL1022485 0.89 SYK (0.37) SMN1; SMN2NPC1RAB9ACYP1A2CYP2A6
SCHEMBL1020759 0.89 SYK (0.37) SMN1; SMN2NPC1RAB9ACYP1A2CYP2A6
SCHEMBL1020487 0.87 NPC1 (0.37) SMN1; SMN2NPC1RAB9AHTR6LTA4H
SCHEMBL1021374 0.86 ALDH1A1 (0.37) TAAR1HTR6ALDH1A1TLR8TLR7
SCHEMBL1020371 0.86 NPC1 (0.39) NPC1RAB9ACYP1A2TAAR1HTR6
SCHEMBL1018388 0.85 ALDH1A1 (0.37) NPC1RAB9ACYP1A2HTR6ALDH1A1
SCHEMBL1019458 0.85 MAPT (0.43) SMN1; SMN2NPC1RAB9ATAAR1HTR6
SCHEMBL1021673 0.84 TAAR1 (0.42) NPC1RAB9ATAAR1HTR6LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP SMN1; SMN2 8/4885NPC1 777/4885RAB9A 1244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.